

REVIEW ESSAY

Prospects & Overviews

The complexity of biological control systems: An autophagy case study

Mariana Pavel¹ | Radu Tanasa² | So Jung Park^{3,4} | David C. Rubinsztein^{3,4} 

¹ Department of Immunology, Grigore T. Popa University of Medicine and Pharmacy of Iasi, Iasi, Romania

² Department of Physics, Alexandru Ioan Cuza University of Iasi, Iasi, Romania

³ Department of Medical Genetics, Cambridge Biomedical Campus, Cambridge Institute for Medical Research/Wellcome Trust/MRC Building, Cambridge, UK

⁴ Cambridge Biomedical Campus, Cambridge Biomedical Campus, UK Dementia Research Institute, Cambridge, UK

Correspondence

David C. Rubinsztein, Department of Medical Genetics, Cambridge Institute for Medical Research, Wellcome Trust/MRC Building, Cambridge Biomedical Campus, Cambridge, UK.

Email: dcr1000@cam.ac.uk

Mariana Pavel and Radu Tanasa authors contributed equally to this work.

Funding information

UK Dementia Research Institute; Romanian Ministry of Research, Innovation and Digitization, CNCS/CCCDI-UEFISCDI, Grant/Award Number: PN-III-P1-1.1-PD-2019-0733; PNCDI-III, Grant/Award Number: POC/448/1/1/127606

Abstract

Autophagy and YAP1-WWTR1/TAZ signalling are tightly linked in a complex control system of forward and feedback pathways which determine different cellular outcomes in differing cell types at different time-points after perturbations. Here we extend our previous experimental and modelling approaches to consider two possibilities. First, we have performed additional mathematical modelling to explore how the autophagy-YAP1 crosstalk may be controlled by posttranslational modifications of components of the pathways. Second, since analogous contrasting results have also been reported for autophagy as a regulator of other transduction pathways engaged in tumorigenesis (Wnt/ β -catenin, TGF- β /Smads, NF- κ B or XIAP/cIAPs), we have considered if such discrepancies may be explicable through situations involving competing pathways and feedback loops in different cell types, analogous to the autophagy-YAP/TAZ situation. Since distinct posttranslational modifications dominate those pathways in distinct cells, these need to be understood to enable appropriate cell type-specific therapeutic strategies for cancers and other diseases.

KEYWORDS

autophagy, cell heterogeneity, mathematical model, precision medicine, transduction pathways, YAP1 signalling

INTRODUCTION

Autophagy is an evolutionarily conserved degradation process for cytoplasmic cargo (ranging from proteins, lipids, nucleotides to entire organelles) within the lysosomes,^[1-3] which plays a pivotal role in the maintenance of both cellular quality control and energetic balance.^[4,5] The physiological relevance of autophagy is related to the normal turnover of the cellular components and the clearance of misfolded long-lived proteins or damaged organelles.^[4,6,7] Under stress conditions, such as starvation or oxidative stress, autophagy is upregulated to degrade dispensable macromolecules and restore nutrient balance.^[8]

A series of autophagy-related (ATG) proteins participate in the main steps of the autophagy pathway: formation of autophagosomal membranes, maturation and final fusion with lysosomes.^[4,5,9] Briefly, downstream of mTORC1 complex inhibition and other signalling cascades, several protein complexes (ULK1/ATG1 complex; class III phosphatidylinositol 3-kinase/VPS34 complex containing Beclin1/BECN1-p150-ATG14; ATG12-ATG5-ATG16L1 complex) are formed, and initiate the assembly of the autophagosomal membranes delivered by ATG9.^[4,5] The microtubule-associated protein 1 light chain 3 (MAP1-LC3 or simply LC3) family of proteins is conjugated to phosphatidylethanolamine in the nascent autophagosome membranes in a defining step in autophagosome biogenesis.^[10] Fully

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2022 The Authors. *BioEssays* published by Wiley Periodicals LLC

formed autophagosomes finally fuse with lysosomes through a process mediated by SNAREs and other proteins proteins.^[3,11]

The destinations, functions, and activities of ATGs or autophagic cargoes are mainly regulated by posttranslational modifications (PTMs) – such as phosphorylation, acetylation, O-GlcNAcylation, ubiquitination, lipidation, glycosylation and proteolysis.^[12] Monitoring the effects that these distinct PTMs have on the overall rate of autophagic degradation enables better definition of the general autophagy pathway control. For instance, phosphorylation of serine and threonine residues regulates the interaction between various ATG proteins to form complexes (e.g., ATG12-ATG5-ATG16L1, ULK1 or VPS34 complexes), modulates the catalytic activities of various kinases (e.g., AMPK, mTOR, ULK1, VPS34), or defines the cellular localisation (nuclear vs. cytoplasm) of the transcription factors involved in the positive (TFEB,^[13] YAP1-TEAD^[14]) or negative (ZKSCAN3^[15]) transcriptional control of autophagy. However, phosphorylation may cause opposite outcomes on the autophagy pathway depending on the target: either induction (when AMPK, ULK1/ATG1, ATG9 or p62 are phosphorylated),^[16–18] or repression of autophagy (p-BECN1).^[19] In addition to being modified by phosphorylation, serine and threonine residues of autophagy proteins can also be modified by the O-GlcNAcylation (O-linked attachment of β -N-acetyl-glucosamine) with similar contrasting effects: autophagy activation, when AMPK is O-GlcNAcylated,^[20] or inhibition, when BECN1 is posttranslationally modified in this way.^[21] Additionally, K63 poly-ubiquitination of aggregate-prone proteins is believed to dictate their degradation via the autophagic-lysosomal route, while the K48 or K11 polyubiquitinated proteins are rather delivered to the ubiquitin-proteasome system (UPS).^[18] Autophagy receptors (such as p62/SQSTM1, NBR1, NDP52, optineurin, VCP) through their ability to bind both LC3/GABARAP (they have a LC3 Interacting Region – LIR domain) and K63 polyubiquitinated proteins (often via an Ub-binding – UBA domain), manage to selectively target specific cargoes to the autophagy pathway.^[22,23] Ultimately, the autophagy receptors are degraded together with their cargoes in autolysosomes.^[24,25]

PTMs impact differently on the autophagy route and can influence the pool sizes of intermediates (including phagophores, autophagosomes, autolysosomes and lysosomes) and/or alter their rates of synthesis, fusion or degradation. These autophagy perturbations further signal to control the transcription of genes, cell growth and proliferation or the balance between cell survival and apoptosis via various transduction pathways. The tight interconnections between autophagy and various signalling routes ultimately dictate cell fate and often serve as the main control systems that define cell identity.^[5,26]

AUTOPHAGY-YAP1 SIGNALLING CROSSTALK: THE BALANCE BETWEEN MULTIPLE FORWARD AND FEEDBACK LOOPS DICTATES THE CELL FATE

We have recently shown that the complex interconnection between the YAP1-WWTR1(TAZ) signalling and autophagy controls cell proliferation and survival with opposite outputs in different cell lines, but

also at different time points of autophagy perturbation. More precisely, we identified α -catenin, the endogenous inhibitor of the Hippo pathway effector YAP1,^[27–29] to be a direct autophagy substrate (via two newly described LIR motifs). Consequently, autophagy positively regulates YAP1 protein levels and activity in a number of cell lines with high basal levels of α -catenins, like the non-malignant mammary epithelial (MFC10A) cells, human embryonic kidney (HEK293T) cells, human cervical epithelium (HeLa) cells, primary mouse embryonic fibroblasts (pMEFs) or primary mammary epithelial cells (pMECs).^[26,30] On the other hand, previous studies have identified that Yap1 itself is an autophagy substrate (independently of p62 expression), and have further shown, using in vivo models (Atg7KO mice) or hepatocyte cell lines (Atg7-deficient murine AML12, or human THLE5B), that autophagy negatively impacts Yap1 activity, as Atg7-deficiency leads to the accumulation of active Yap1 that increases liver size, causing progenitor cell expansion with hepatocarcinogenesis.^[31] This result was also confirmed by us using various hepatocyte cell lines (THLE2, HepG2, Huh7 cells) or non-small cell lung cancer cells (A549 cells), as all these cells have a low basal protein expression of α -catenins.^[26,30] In other words, one may conclude that cells that have the capacity to bind a significant portion of the YAP1 pool by α -catenins will respond to autophagy inhibition by reducing cell proliferation, size and migration capacities, while cells that have transcriptional changes or PTMs that overcome or lower this interaction will behave in completely opposite way, as the direct ability of autophagy to degrade YAP1 will be dominant: autophagy inhibition would activate YAP1 (Figure 1A). From a general perspective, one may summarise that the initial post-translational status is crucial in defining the direction of response to any external/internal perturbation (of autophagy or other metabolic pathways).

The autophagy-YAP1 picture is further entangled by a feedback path, since YAP1 regulates autophagy. We previously also showed that YAP1/TAZ positively modulates autophagy by upregulating the transcriptional expression of myosin-II genes in a series of cell lines, like MFC10A, HeLa cells, human keratinocyte (HaCaT) cells, pMEFs or pMECs.^[14] Other studies have confirmed this general observation that YAP1 is required for proper autophagy, but suggest various distinct mechanisms. YAP1 transcriptional targets include Armus, a protein of the RAB-GAP family, which is required for the proper fusion of autophagosomal vesicles with lysosomes,^[32] and HMGB1, the well-known activator of Beclin-1 (which displaces the inhibitor protein Bcl-2 from its interaction with Beclin-1)^[33,34] in human glioma (U251 and U87)^[35] cell lines. Autophagy flux is further increased by the interaction of YAP1 with the master transcription factor EB (TFEB)^[36] or TEAD^[37] and co-transcriptional regulation of autophagy and lysosomal genes in neonatal rat cardiomyocytes and human breast cancer cells (MCF7 or MDA-MB-231). This feedback loop (of YAP1 controlling autophagy) is important; as mathematical modelling suggests that the strength of the effect exerted by YAP1 on autophagy controls the magnitude of the YAP activity outcome after autophagy perturbations (Figure 1B). For instance, in cells with low basal α -catenin protein levels, events that enhance the control of YAP over the autophagy pathway will lead to a lesser increase in YAP activity than the cases with negligible feedback effects upon autophagy




FIGURE 1 Schematic representation of the autophagy-YAP1 signalling control system. (A) The two contrasting effects of autophagy on cell survival and proliferation resulting from degrading either α -catenin (YAP1 inhibitor) or YAP1 are named as *positive* and *negative forward paths*, respectively. Various posttranslational modifications (PTMs) impact differently on the strengths of the two forward paths. The *positive feedback path* is represented by the transcriptional control exerted by YAP1 (in conjunction with TFEB or TEAD) on key autophagy genes. (B) Schematic diagram of the effect caused by the feedback path/loop in cells with either low or high basal levels of α -catenins, and normal or high initial autophagy flux/activity. The strength of the feedback loop is denoted by the parameter v_Y . Y_{init} indicates the initial YAP1 activity. YAP1 activity increases in low basal α -catenin conditions ($YAP > Y_{init}$), and decreases in high basal α -catenin cells ($YAP1 < Y_{init}$) upon autophagy inhibition

inhibition. In cells with high basal α -catenin expression, a high feedback effect (of YAP1 controlling autophagy) will cause a lesser reduction in the YAP activity output upon autophagy compromise, but only at earlier time points.^[26,30] For cancer cells,^[38] the typically heightened autophagy flux is expected to cause an increase in the magnitude of the observed effect only for the low α -catenin cases. A second general observation could be made at this point: the feedback paths control the magnitude of the investigated effects in a time-dependent manner.

PROPOSED MATHEMATICAL MODEL FOR THE AUTOPHAGY-YAP1 SIGNALLING CROSSTALK

One may ask how these apparently contradicting observations (positive and negative controls) can be integrated to define a general model for a particular pathway (e.g., autophagy-YAP/TAZ) to enable a better understanding of the outputs empirically observed after various perturbations, and to allow prediction of the cellular behaviour in new situations.

To answer this question, we previously developed a mathematical model of three interconnected differential equations that describe the dynamics of the three key players (autophagy, YAP1 activity and α -catenin levels) in a time-dependent manner, starting from the three main constituent processes (Figure S1, Supporting Information):^[26] i) autophagy positively modulates YAP1 activity by degrading its inhibitor, α -catenin (so-called *positive forward path*; the α -catenin that accumulates upon autophagy inhibition interacts with YAP1 and sequesters it into the cytoplasm);^[27] ii) autophagy negatively modulates YAP1 activity by facilitating its direct degradation (so-called *negative forward path*; active-YAP1 accumulates upon autophagy inhibition);^[31] iii) the feedback path of YAP1 positively controlling autophagy (by monitoring autophagosome formation, maturation, and fusion with lysosomes).^[14,36] Thus, during autophagy inhibition, the rate of autophagy decrease is controlled by both the decay rate due to the applied perturbation (parameter c),^[26,39] and the strength of the feedback path (parameter v_Y). The rate of YAP1 variation relies on the balance between the strengths of the two, *positive* (controlled by parameter r_1 , which defines the strength of the cytosolic-sequestration rate of YAP1 by α -catenins) and *negative* (controlled by parameter r_2 , which defines the strength of active-YAP1 accumulation rate upon autophagy inhibition) *forward paths*, while the rate of α -catenin accumulation depends on its degradation rate by autophagy (controlled by parameter r_3). It is also important to note that the intracellular compartmentalisation of various key players may vary, based on the cell type and nutrient/environmental conditions, and thus will influence the values of r_1 , r_2 and r_3 parameters. For example, nutrient rich conditions activate mTOR on peripheral lysosomes, which inhibits autophagy and promotes YAP1 activation (increased r_2 value)^[40,41] or α -catenin accumulation (increased r_3 value).

In our previous study, using this mathematical model, we were able to reconcile the controversial observations present in the field of YAP1 and autophagy research and identify basal α -catenin levels (by appropriate experimental validation) as the main driver for the direction of YAP output (activation/inhibition) upon autophagy perturbation with considerable input in the magnitude of the effect offered by the strength of the feedback path (so called parameter v_Y). Additionally, the other parameters (c , r_1 , r_2 and r_3) were assumed as constants for the numerical simulations, their values being extrapolated from experimental observations.

However, if one wants to extend the model to a broader range of cell types and systems, the variations in these parameters (c , r_1 , r_2 and r_3) should be carefully considered. Thus, we considered possible scenarios that would lead to variations in order to understand, at least theoretically, their potential impact over the outputs.

The autophagy decay rate, modelled by parameter c , dictates the YAP1 output in low basal α -catenin cells and/or low feedback strength conditions

The autophagy decay rate (parameter c) may vary, as it depends on the nature of the perturbation stimulus: if there is a chemi-

cal (inhibitors/activators that may require minutes-hours to impact autophagy) or genetic manipulation (siRNA knockdown experiments with visible effects in hours-days, or knockout cell lines – days-weeks). As most of our experiments were siRNA knockdown experiments and had prolonged treatments, the autophagy decay rate was relatively slow. Interestingly, increasing the value of parameter c (as would occur in biological systems exposed to a rapid perturbation decay rate) can change the outcome of the output effect (e.g., YAP1 activity) in cells characterised by low basal α -catenin and/or little feedback effect (low v_Y): switching from YAP1 activation (what we observed in our recent publications)^[26,30] to YAP1 inhibition – Figure 2A. Conversely, the effect exerted by the autophagy decay rate in biological systems characterised by both high α -catenin levels and a strong feedback effect (high v_Y), is almost neglectable – Figure 2A and Figure S2, Supporting Information. The initial levels of autophagy and YAP1 activity only impact on the magnitude/extent of the final outcome (e.g., reducing the basal autophagy levels or initial YAP1 activity will produce the same effect – of either activation or inhibition, but to a lower extent) – Figure S3, Supporting Information.

The strength of the positive forward path, modelled by parameter r_1 , dictates the YAP1 output in low basal α -catenin cells

Regarding the cases where the strength of the cytosolic interaction between YAP1 and α -catenin varies, which influences the strength of the *positive forward path*, it is worth considering the possibilities of PTMs that facilitate (e.g., phosphorylation of YAP1) or disrupt this protein-protein interaction. The disruption may be caused by PTMs like ubiquitination, that amplifies the proteasomal-mediated degradation of YAP1 and/or α -catenins and/or 14-3-3 proteins (which are the molecules that intermediate the interaction between YAP1 and α -catenin), or acetylation of 14-3-3 proteins that shut-off their functions as intermediary binding partners.^[42,43] The strength of the *positive forward path* is controlled by the value of parameter r_1 . For instance, a relatively moderate increase in parameter r_1 (e.g., doubling its value) would cause a decrease in the YAP1 activity in low basal α -catenin cells, even reversing the final output effect at later time points of autophagy perturbation (switching from the previously expected YAP1 activation to YAP1 inhibition) – Figure 2B. The YAP1 activity in cells with high basal α -catenins is not sensitive to moderate changes (up to twofold increase) of this parameter – Figure 2B and Figure S4, Supporting Information.

The strength of the negative forward path, modelled by parameter r_2 , dictates the YAP1 output in low basal α -catenin cells

When considering the effect caused by the strength of active-YAP1 accumulation rate upon autophagy inhibition (controlled by parameter r_2 – Figure S1, Supporting Information), over final YAP1 activity, it is




FIGURE 2 Schematic representation of the effects exerted by the variation of c , $r1$ and $r2$ parameters upon autophagy inhibition. (A) Variation of parameter c (the autophagy decay rate due to external perturbation): increase in the rate of autophagy decrease should cause YAP1 inhibition, and not activation at later time points in cells with low basal α -catenin protein levels. (B) Variation of parameter $r1$ (controls the strength of the positive forward effect on YAP1 activity) and (C) $r2$ (controls the strength of the negative forward effect on YAP1 activity): increasing $r1$ or reducing $r2$ lowers the YAP1 activity, even causing YAP1 inhibition at later time points of autophagy inhibition in cells with low basal α -catenin protein levels

important to understand the dynamics of the process. For instance, a system characterised by an increased cytosolic YAP1 delivery rate into autophagosomes (and followed by an accelerated autophagosome-lysosome fusion rate) would actually show a *reduction in the active-YAP1 accumulation rate* at earlier time points of autophagy inhibition using siRNA experiments targeting key ATGs: while the number of newly forming autophagosomes decreases (as this is not an instant process, rather a prolonged one that takes hours-days), the remaining autophagosomes are trying to maximise the cytosolic YAP1 degra-

dation, being still able to deliver it into lysosomes, at the extent of the active-YAP1 accumulation rate. While the YAP1 delivery rate into autophagosomes depends rather on the cytoplasmic pool of YAP1 and its autophagy receptors, YAP1 clearance is rather linked to autolysosome formation and degradation capacity.

In situations characterised by a decreased accumulation rate of active-YAP1 (which is defined by a decreased value of parameter $r2$), it is worth mentioning the types of PTMs that facilitate the proper cytosolic YAP1 delivery into autophagosomes by promoting




FIGURE 3 Schematic representation of YAP1 activity upon autophagy inhibition when one arm of the forward path is dominant. When the two arms (positive or negative) of the forward path are not balanced, the dominating arm dictates the YAP output irrespective of the initial α -catenin levels. For instance, a large increase in negative arm (controlled by r_2 parameter; over five times) or large decrease in the positive arm (controlled by parameter r_1) would increase the YAP1 activity upon autophagy inhibition at early-time points irrespective of the initial α -catenin levels. Conversely, a large reduction in the negative arm would cause the opposite effect: decreased YAP1 activity upon autophagy inhibition irrespective of the initial α -catenin levels

its interaction with various cytosolic autophagy receptor proteins, like p62, NBR1, co-chaperone BAG3 (phosphorylation of YAP1 and various components of the autophagy machinery – LC3, GABARAP, GABARAPL1, ATG9, ATG31-ATG29 complex; YAP1 ubiquitination linked to K63 or K27;^[12] or decreased YAP1 O-GlcNAcylation – that causes YAP1 instability and promotes its degradation),^[44] or increased autophagosome-lysosome fusion and recycling (e.g., dephosphorylation of TFEB).^[13] The r_2 decrease displays a similar trend as r_1 increase over the outcome. For instance, a relatively moderate reduction in parameter r_2 (e.g., decrease by half) would lessen the YAP1 activity, even reversing the expected output phenotype in low basal α -catenin cells at later time points of autophagy perturbation (switching from the previously expected YAP1 activation to YAP1 inhibition) – Figure 2C and Figure S5, Supporting Information. Changes in the initial levels of autophagy, YAP1 or the strength of the feedback path only impact the magnitude of the output measures – Figure S6, Supporting Information. Interestingly, if there is a high discrepancy between the strengths of the two *positive* (defined by parameter r_1) and *negative* (defined by parameter r_2) forward paths, the effect caused by distinct basal α -catenin levels is only minor. For instance, if the strength of the direct YAP1 autophagic accumulation rate (*negative forward path*) is five times higher than the strength of the YAP1 cytosolic sequestration rate by α -catenins (*positive forward path*) (ratio of r_2/r_1 – Figure 3), one may observe that the cells with high basal α -catenin expression start to behave similarly to those with initially low α -catenins levels at early-time points: they increase the YAP1 activity output – Figure 3 and Figure S7, Supporting Information. The effect of variations in parameter r_3 (the rate of α -catenin accumulation) over the final YAP1 activity levels is only minor if compared to the r_1 and r_2 parameters – Figure S8, Supporting Information. Importantly, the autophagic flux is additionally regulated, at least in yeast, by the number and size of the form-

ing autophagosomes, which directly correlates with the cellular pool of Atg8, the ortholog of the mammalian LC3 protein.^[45–48]

To summarise what we generally learnt from our proposed model:

1. distinct basal expression levels of one single protein (e.g., α -catenins) is sufficient to define the cell fate upon external/internal perturbations;
2. distinct time periods of applied perturbations may cause contradictory outcomes in the same cellular system;
3. the strength of the feedback path (e.g., YAP1 controlling autophagy) impacts on the magnitude of the outcome, but has only minor effects on the cell fate (i.e., directionality of outcome);
4. PTMs (e.g., responsible for controlling the strength of the positive and negative forward paths exerted by autophagy over YAP1 activity) may influence the cell fate in cells with low expression of inhibitors;
5. if one of the contrasting effects is predominant, it may override the outcome irrespective of any other basal conditions.

CROSSTALK BETWEEN AUTOPHAGY AND OTHER INTRACELLULAR TRANSDUCTION PATHWAYS: FORWARD AND FEEDBACK PATHS

The aforementioned posttranslational and transcriptional interconnections between YAP1/TAZ (Hippo signalling) and autophagy with opposite outputs in different cell lines, at distinct time-points of autophagy perturbation, may reflect processes that underlie some of the apparent cell-type specific discrepancies in cellular responses to autophagy, involving other pathways.

The previous mathematical-numerical model used for explaining the autophagy-YAP1 link might serve as an exemplar that could be extended to autophagy and its cross-talk with other transduction pathways (Wnt/ β -catenin signalling, TGF- β /Smads signalling, NF- κ B or XIAP/cIAP-mediated cell survival) where similar major axes have been identified: a) a *positive* forward path, when autophagy indirectly up-regulates that particular signalling pathway (e.g., autophagy degrades the pathway's inhibitors); b) a *negative* forward path, when autophagy directly inhibits the signalling (e.g., autophagy directly degrades the pathway's components); c) a feedback regulatory path exerted by the transduction pathway over autophagy. Further insights that may connect the contrasting, but extremely valuable observations from the literature in the field of autophagy and intracellular signalling are indeed required. In the following sections, we consider some possibilities that may inform future efforts aiming to reconcile apparent contradictions in the literature.

Autophagy and Wnt/ β -catenin signalling

Autophagy was shown to positively regulate the activation of Wnt/ β -catenin signalling in hepatocellular carcinoma cells, causing increased cancer cell glycolysis.^[49] On the other hand, it has been reported




FIGURE 4 Schematic representation of various autophagy-transduction pathways control systems. (A) Autophagy-Wnt/β-catenin signalling crosstalk. Both forward and feedback paths present two arms: positive and negative. (B) Autophagy-TGF-β/Smads signalling crosstalk. The forward path present two arms: positive and negative, while the feedback is only positive

that autophagy induction was able to repress the Wnt/β-catenin signalling pathway by stimulating the autolysosomal degradation of key pathway-components, like β-catenin^[50] and Dishevelled (Dvl)^[51] – Figure 4A. If β-catenin is directly delivered to the forming autophagosomal membranes (a LIR-mediated process) in a series of cell lines (HT29 and RKO carcinoma-derived cell lines, HEK293T cells, HCT116 cells, intestinal epithelial mouse cells), Dvl2 first requires PTMs (ubiquitylation mediated by the von Hippel-Lindau/VHL protein) that would favour its aggregation and binding to p62, which further mediates the delivery of Dvl2 to the autophagy-lysosomal system in cell lines like HeLa, HEK293T, SW480 and immortalised mouse embryonic fibroblasts (MEFs) or biopsy pieces from human colon carcinoma tissues.^[51] The feedback loop caused by Wnt/β-catenin controlling autophagy complicates the picture, as Wnt/β-catenin signalling (activated through the Wnt3 ligand) positively regulates autophagy in squamous cell carcinoma of the head and neck, promoting the cancer cell radioresistance.^[52] Conversely, other studies have shown that the Wnt/β-catenin pathway negatively modulates autophagy: activation of this signalling route attenuated Beclin-1-dependent autophagy in human osteosarcoma cells, while inhibition led to increased expression of key autophagy genes (e.g., *LC3B*, *BECN1*, *P62*), and downregulation of

autophagy inhibitory proteins (e.g., Bcl-2) in multiple myeloma cells,^[53] glioblastoma cells^[54] or mammary epithelial cells.^[55]

Autophagy and TGF-β/Smads signalling

For the TGF-β signalling and autophagy link, two distinct studies, one from Javad Alizadeh and co-workers studying TGF-β1, and another one by Yan Sun et al focusing on TGF-β2, have shown that autophagy positively modulates the TGF-β/Smads signalling-induced epithelial to mesenchymal transition (EMT), cellular migration and contraction in non-small cell lung cancer cells (NSCLC – A549, H1975 cell lines),^[56] and primary rabbit lens epithelial cells by controlling the phosphorylation status of Smad2/3 proteins.^[57] A recent study further reinforces these observations, supporting the role of autophagy in mediating the TGF-β/Smads-induced fibrosis in human trabecular meshwork cells (specialised ocular tissue which maintains intraocular pressure) by controlling the transcription of the TGF-β antagonist, BMP and activin membrane bound inhibitor (BAMBI).^[58] With relevance to the innate immune antiviral response, autophagy also triggers the activation of TGF-β production and Smad2/3 signalling in Human respiratory

syncytial virus (RSV)-infected primary mouse macrophages and -RAW 264.7 (mouse macrophage cell line) cells to induce the production of optimal IFN- β ^[59] – Figure 4B.

This biology appears to include a negative regulation loop, as it has been reported that autophagy degrades TGF- β , reducing the protein levels without alterations in the mRNA levels, in primary mouse renal tubular epithelial cells (RTEC) and human HK-2 (human proximal RTEC) cells.^[60] For the feedback loop (how the TGF- β signalling controls autophagy), multiple studies have shown that TGF- β signals by upregulating the expression of key autophagy genes (*LC3B*, *BECN1*, *ATG5*, *ATG7*), and thus induces autophagy, which, in turn, facilitates the phosphorylation status of Smad2/3 to control fibrosis in primary human atrial myofibroblasts^[61] or cell growth in HuH7 (human hepatocellular carcinoma) cells, MDA-MB-231 (mammary carcinoma) cells^[62] or normal bovine mammary epithelial BME-UV1 cells.^[63] Interestingly, a recent study described that TGF- β signals through Smad proteins to induce TFEB expression and facilitate the TFEB-driven autophagy in a panel of pancreatic cancer cell lines (e.g., MIA PaCa-2, PANC-1, Panc03.27 lines) and patients' tissues.^[64]

Autophagy and NF- κ B signalling

NF- κ B transcription factors are key regulators of cell survival and aberrant NF- κ B signalling has been involved in the pathogenesis of most human malignancies. The cross-talk between NF- κ B signalling and autophagy is also complex. For instance, autophagy positively regulates NF- κ B signalling by promoting the degradation of its well-known inhibitor I κ B α in a set of intestinal epithelial cell lines (HT29, HCT116, HCT15, HCA7, SW48, RKO and HCT8) and MEFs.^[65]

Interestingly, autophagy also negatively impacts NF- κ B signalling by promoting the degradation of key activators (IKK α , β , γ and NIK – the activator of IKK) by several mechanisms – Figure 5. One mechanism implies that the autophagic degradation of IKK is accelerated in the absence of its binding-partner Hsp90 and independently of its ubiquitination status in HEK293, Jurkat cells, Human B-cell line Ramos RG69, mouse fibroblasts ts20 and MEFs.^[66] Kelch-like ECH-associated protein 1 (KEAP1), an E3 ubiquitin ligase, further promoted the delivery of IKK β to the autolysosomal system for degradation by competing with HSP90 for the direct binding to IKK β . KEAP1, in addition to diminishing the expression of IKK β , also causes inactivation of IKK β by reducing its phosphorylation status in HEK293 and HeLa cells.^[67] Another E3 ubiquitin ligase, Ro52, facilitates the monoubiquitination of the phosphorylated active form of IKK β induced by the Tax oncoprotein of HTLV-1, a PTM involved in the subcellular translocation of the active IKK β to autophagosomes with subsequent lysosomal degradation, leading to the inactivation of NF- κ B pathway in HEK293 and HeLa cells.^[68] The active IKK β may also be delivered to autophagosomes via an adaptor protein, an F-box protein, S-phase kinase associated protein 2 (SKP2), that bridges IKK β and the autophagic cargo receptor p62, thus promoting p62-mediated selective autophagic degradation of IKK β followed by NF- κ B inhibition in HEK293 and HeLa cells.^[69] With relevance to the

innate immune anti-bacterial response, Atg7 was found as a binding partner for phosphorylated I κ B α . Thus, the loss of Atg7 (independently of autophagy) led to the release of p-I κ B α from the interaction, promoting its ubiquitination and UPS-mediated degradation, and ultimately triggering NF- κ B activation in murine macrophages.^[70] ATG5 deficiency also augmented NF- κ B-mediated inflammation in proximal tubular epithelial cells.^[71]

This pathway may also involve a feedback loop (how NF- κ B impacts autophagy pathway?), as several studies have confirmed that NF- κ B/IKK signals to stimulate autophagy by up-regulating the expression of several genes involved in the formation and maturation of the autophagic machinery (e.g., *BECN1*, *ATG5*, *LC3*, *LAMP1*, *RAB7*) in a set of cell lines including MEFs,^[72] HeLa and MCF10A cells.^[73] However, NF- κ B also suppresses autophagy, by upregulating the expression of several well-known autophagy repressors (A20, Bcl-2 family members, phosphatase and tensin homolog/mammalian target of rapamycin (PTEN/mTOR) and nitric oxide (NO)), and/or by suppressing some autophagy inducers (Bcl-2 interacting protein 3 (BNIP3), JNK1, p53 and ROS) in distinct cell lines and time points after perturbation/signalling (rat primary cortical neurons, MEFs, HeLa, immature B cell lymphoma WEHI 231 cells and sarcoma cells).^[74–77]

NF- κ B signalling has been associated to the upregulation of several inhibitors of apoptosis (IAPs) family members, including cellular inhibitor of apoptosis 1 (cIAP1) and 2 (cIAP2), X chromosome-linked inhibitor of apoptosis (XIAP).^[78–82]

Autophagy and XIAP/cIAP-mediated cell survival

Controversial literature also exists for the role of autophagy in controlling the balance between cell survival and apoptosis. If one searches for the links between the E3 ubiquitin ligases, XIAP/cIAPs and autophagy, one may observe that short periods of autophagy activation promote cell survival via NF- κ B mediated upregulation of anti-apoptotic genes (Bcl-2,^[83] Bcl-XL, XIAP, cIAP1, cIAP2...) in various cancer cell types: human glioma cell lines (A172, U87, U251 cell lines),^[84] fibrosarcoma cell lines or human diffuse large B cell lymphoma cell lines (DLBCL – RIVA, OCI-LY3, SUDHL-2, HBL-1 and SUDHL-5).^[78,85–87] However, induction of autophagy by timosaponin AIII caused the lysosomal degradation of ubiquitinated XIAP and induced apoptosis in hepatocarcinoma cells.^[88] The critical role of ubiquitination as a PTM in facilitating the autophagy-dependent proteolysis of XIAP was also confirmed using E1 enzyme inhibitors.^[88] In support of these last findings, prolonged autophagy induction with rottlerin caused apoptosis by down-regulating the expression levels of XIAP, cIAP-1, Bcl-2 and Bcl-XL protein levels in pancreatic cancer stem cells^[89] – Figure 6.

When considering the feedback loop (how XIAP/cIAP1/2 proteins impact on autophagy?), it is important to highlight that XIAP and cIAP1, through their E3 ubiquitin ligase activities, positively regulate autophagy: either by increasing the NF- κ B capacity to promote the transcription of *BECN1* in HeLa, MEFs, MCF10A and DLBCL cell lines (SUDHL-5, SUDHL-8 and SUDHL-10),^[73] or by assisting the efficient fusion of lysosomes with autophagosomes in HeLa, MEFs and dermal




FIGURE 5 Schematic representation of the autophagy-NF-kB signalling control system. Both forward and feedback paths present two arms: positive and negative




FIGURE 6 Schematic representation of the autophagy-XIAP/cIAP signalling control system. Both forward and feedback paths present two arms: positive and negative, each of them with multiple mechanisms

fibroblasts.^[90] Other studies have shown the opposite effect of XIAP on autophagy by a distinct mechanism: phosphorylated active XIAP acts as an E3 ligase that mediates the rapid proteasomal degradation of Mdm2 (the major ubiquitin E3 ligase and inhibitor of p53), thus upregulating the cytosolic p53 levels which ultimately suppress autophagy.^[91] This last effect was shown in a set of cell lines also used in the previ-

ous studies (MEFs and MCF10A cells) and additional ones (HCT116, HepG2, HEK293T, A549, MCF7 cells), but using different time points of exposure and concentrations of the XIAP inhibitor, embelin: short periods (1–4 h) and very low concentrations (50–200 nM)^[91] versus longer time periods (16 h) at higher concentrations of 10–20 μ M in another study.^[73] Additional studies have found that XIAP acts as an E3 ubiqui-

tin ligase for p62, promoting its UPS-mediated degradation, thus suppressing the p62-selective autophagy in HCT116, HepG2, HEK293T, A549 and MDA-MB-cells.^[92]

These different interactions between autophagy and diverse signalling pathways suggest that distinct initial conditions (intracellular networks and PTMs) may explain why various studies have obtained contrasting results when using different biological systems, or even the same systems but unrelated time points (or concentrations) of perturbations/treatments.

CONCLUDING REMARKS AND OPEN QUESTIONS

We believe that multiple points of influence determined by PTMs (phosphorylation, ubiquitylation, acetylation, O-GlcNAcylation...), apart from the basal protein expression, modify the final outcomes in biological systems and define cell fate, acting as a switch on/off button. For example, both abnormal acetylation and deacetylation are associated with pathological conditions, particularly neurodegenerative diseases and cancer.^[93–95] Our experimental observations, explained through a simple mathematical model, point out that a heterogeneous biological system (same cell type, but with slightly different basal conditions or altered posttranslational processes) leads to different outcomes at the individual cell level and at different time points after perturbation. This supposition may explain how tumorigenic changes might start in only one or few cells in a dynamic process of alternating on-off steps, as the parameters involved might vary over time and space (e.g., transcriptional or PTMs caused by various environmental perturbations).

Our model for understanding the crosstalk between a signalling pathway and autophagy might provide insight into therapeutic opportunities in a variety of cancers (hepatocarcinoma, pancreatic adenocarcinoma, breast cancers, cancers of the head and neck, etc.). Nevertheless, multiple parameters bring complexity to the system being considered, but, at the same time shed light on the importance of understanding tissue heterogeneity. This highlights the requirement for single cell analysis to assess transcriptional and post-translational modification levels in order to achieve the proper understanding of the biological processes that characterise the patient's cancer cells, by integrating single-cell fluorescence analysis of autophagy,^[48] with data acquired from high-throughput omics platforms and machine-learning algorithms.^[96,97] This may allow for the identification of intracellular changes that need to be repaired for reversing the cellular status to a benign state. Importantly, any biological process should be followed kinetically, as the same perturbation applied for different time periods might end up with contrasting outcomes.

Perturbing a metabolic process, either autophagy or any other catabolic/anabolic route, will inevitably impact on multiple transduction pathways. For instance, when common cancer hallmarks (increased cell proliferation, cell glycolysis) are investigated as read-outs, one should be careful in designing the experiments and interpreting the data: the initial perturbation of one cellular process (e.g., autophagy) will disturb multiple signalling cascades with contrasting

effects. For example, cell proliferation, differentiation and/or survival are promoted by YAP1, Wnt, and NF- κ B signalling, but are inhibited by TGF- β . Nevertheless, these signalling routes may react differently at various time points, as different axes are switched on/off at early versus late responses, or short versus long perturbations: short periods of autophagy induction promote resistance to cell death via NF- κ B, while longer activation may induce autophagy-dependent cell death.^[98–100] The system biology is further complicated and controlled, apart from the feedback loops, by the vast regulatory links (many still unknown) existing between the different axes affected by the initial perturbation (e.g., autophagy), and systems-level properties of the control networks can be integrated into relevant mathematical models.^[26,30,83,100,101] Thus, the cellular biological complexity requires further in-depth study. However, high priority should be given to gathering and merging the existing research information to define the integrated relevant cellular networks using specialised bioinformatics platforms to facilitate the understanding and prediction of cell responses to external/internal stimuli with relevance to designing successful precision therapies.

ACKNOWLEDGEMENTS

We are grateful for funding from the UK Dementia Research Institute (funded by MRC, Alzheimer's Research UK and the Alzheimer's Society), a grant of the Romanian Ministry of Research, Innovation and Digitization, CNCS/CCCDI-UEFISCDI, project number PN-III-P1-1.1-PD-2019-0733, within PNCDI-III, and POC/448/1/1/127606 CENEMED project (M.P.).

CONFLICT OF INTEREST

D.C.R. is a consultant for Drishti Discoveries, Abbvie, PAQ Therapeutics, Aladdin Healthcare Technologies SE and Nido Biosciences. All other authors declare no competing interests.

AUTHOR CONTRIBUTIONS

Mariana Pavel and Radu Tanasa created the computer simulations and prepared the related figures. All authors commented the results and wrote the manuscript together. David C. Rubinsztein supervised the study.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

David C. Rubinsztein  <https://orcid.org/0000-0001-5002-5263>

REFERENCES

1. Weidberg, H., Shvets, E., & Elazar, Z. (2011). Biogenesis and cargo selectivity of autophagosomes. *Annual Review of Biochemistry*, 80, 125–156. <https://doi.org/10.1146/annurev-biochem-052709-094552>
2. De Duve, C., & Wattiaux, R. (1966). Functions of lysosomes. *Annual Review of Physiology*, 28, 435–492. <https://doi.org/10.1146/annurev-ph.28.030166.002251>

3. Djajadikerta, A., Keshri, S., Pavel, M., Prestil, R., Ryan, L., & Rubinshtein, D. C. (2020). Autophagy induction as a therapeutic strategy for neurodegenerative diseases. *Journal of Molecular Biology*, 432(8), 2799–2821. <https://doi.org/10.1016/j.jmb.2019.12.035>
4. Menzies, F. M., Fleming, A., Caricasole, A., Bento, C. F., Andrews, S. P., Ashkenazi, A., & Rubinshtein, D. C. (2017). Autophagy and neurodegeneration: Pathogenic mechanisms and therapeutic opportunities. *Neuron*, 93(5), 1015–1034. <https://doi.org/10.1016/j.neuron.2017.01.022>
5. Pavel, M., & Rubinshtein, D. C. (2017). Mammalian autophagy and the plasma membrane. *Febs Journal*, 284(5), 672–679. <https://doi.org/10.1111/febs.13931>
6. Ashkenazi, A., Bento, C. F., Ricketts, T., Vicinanza, M., Siddiqi, F., Pavel, M., Squitieri, F., Hardenberg, M. C., Imarisio, S., Menzies, F. M., & Rubinshtein, D. C. (2017). Polyglutamine tracts regulate autophagy. *Autophagy*, 13(9), 1613–1614. <https://doi.org/10.1080/15548627.2017.1336278>
7. Pavel, M., & Rubinshtein, D. C. (2013). Autophagy upregulation as a therapeutic strategy for neurodegenerative diseases. In F. E. Fang & B. T. Ng (Eds.), *Antitumor potential and other emerging medicinal properties of natural compounds* (pp. 227–238). Springer.
8. Singh, R., & Cuervo, A. M. (2011). Autophagy in the cellular energetic balance. *Cell Metabolism*, 13(5), 495–504. <https://doi.org/10.1016/j.cmet.2011.04.004>
9. Behrends, C., Sowa, M. E., Gygi, S. P., & Harper, J. W. (2010). Network organization of the human autophagy system. *Nature*, 466(7302), 68–76. <https://doi.org/10.1038/nature09204>
10. Klionsky, D. J., Abdel-Aziz, A. K., Abdelfatah, S., Abdellatif, M., Abdoli, A., & Abel, S., & Tong, C.-K. (2021). Guidelines for the use and interpretation of assays for monitoring autophagy. (4th edition). *Autophagy*, 17(1), 1–382. <https://doi.org/10.1080/15548627.2020.1797280>
11. Bento, C. F., Renna, M., Ghislat, G., Puri, C., Ashkenazi, A., Vicinanza, M., Menzies, F. M., & Rubinshtein, D. C. (2016). Mammalian autophagy: How does it work? *Annual Review of Biochemistry*, 85, 685–713. <https://doi.org/10.1146/annurev-biochem-060815-014556>
12. Wani, W. Y., Boyer-Guittaut, M., Dodson, M., Chatham, J., & Darley-Usmar, V., & Zhang, J. (2015). Regulation of autophagy by protein post-translational modification. *Laboratory Investigation*, 95(1), 14–25. <https://doi.org/10.1038/labinvest.2014.131>
13. Settembre, C., Di Malta, C., Polito, V. A., Garcia Arencibia, M., Vetrini, F., Erdin, S., & Ballabio, A. (2011). TFEB links autophagy to lysosomal biogenesis. *Science*, 332(6036), 1429–1433. <https://doi.org/10.1126/science.1204592>
14. Pavel, M., Renna, M., Park, S. J., Menzies, F. M., Ricketts, T., Fullgrabe, J., Ashkenazi, A., Frake, R. A., Lombarte, A. C., Bento, C. F., Franze, K., & Rubinshtein, D. C. (2018). Contact inhibition controls cell survival and proliferation via YAP/TAZ-autophagy axis. *Nature Communication*, 9(1), 2961. <https://doi.org/10.1038/s41467-018-05388-x>
15. Chauhan, S., Goodwin, J. G., Chauhan, S., Manyam, G., Wang, J., Kamat, A. M., & Boyd, D. D. (2013). ZKSCAN3 is a master transcriptional repressor of autophagy. *Molecular Cell*, 50(1), 16–28. <https://doi.org/10.1016/j.molcel.2013.01.024>
16. Papinski, D., Schuschnig, M., Reiter, W., Wilhelm, L., Barnes, C. A., Maiolica, A., & Kraft, C. (2014). Early steps in autophagy depend on direct phosphorylation of Atg9 by the Atg1 kinase. *Molecular Cell*, 53(3), 471–483. <https://doi.org/10.1016/j.molcel.2013.12.011>
17. Matsumoto, G., Wada, K., Okuno, M., Kurosawa, M., & Nukina, N. (2011). Serine 403 phosphorylation of p62/SQSTM1 regulates selective autophagic clearance of ubiquitinated proteins. *Molecular Cell*, 44(2), 279–289. <https://doi.org/10.1016/j.molcel.2011.07.039>
18. Xie, Y., Kang, R., Sun, X., Zhong, M., Huang, J., Klionsky, D. J., & Tang, D. (2015). Posttranslational modification of autophagy-related proteins in macroautophagy. *Autophagy*, 11(1), 28–45. <https://doi.org/10.4161/15548627.2014.984267>
19. Wang, R. C., Wei, Y., An, Z., Zou, Z., Xiao, G., Bhagat, G., White, M. Reichelt, J., & Levine, B. (2012). Akt-mediated regulation of autophagy and tumorigenesis through Beclin 1 phosphorylation. *Science*, 338(6109), 956–959. <https://doi.org/10.1126/science.1225967>
20. Bullen, J. W., Balsbaugh, J. L., Chanda, D., Shabanowitz, J., Hunt, D. F., Neumann, D., & Hart, G. W. (2014). Cross-talk between two essential nutrient-sensitive enzymes: O-GlcNAc transferase (OGT) and AMP-activated protein kinase (AMPK). *Journal of Biological Chemistry*, 289(15), 10592–10606. <https://doi.org/10.1074/jbc.M113.523068>
21. Marsh, S. A., Powell, P. C., Dell'italia, L. J., & Chatham, J. C. (2013). Cardiac O-GlcNAcylation blunts autophagic signaling in the diabetic heart. *Life Sciences*, 92(11), 648–656. <https://doi.org/10.1016/j.lfs.2012.06.011>
22. Kirkin, V., McEwan, D. G., Novak, I., & Dikic, I. (2009). A role for ubiquitin in selective autophagy. *Molecular Cell*, 34(3), 259–269. <https://doi.org/10.1016/j.molcel.2009.04.026>
23. Lippai, M., & Low, P. (2014). The role of the selective adaptor p62 and ubiquitin-like proteins in autophagy. *BioMed Research International*, 2014, 832704. <https://doi.org/10.1155/2014/832704>
24. Kirkin, V., Lamark, T., Sou, Y. S., Bjorkoy, G., Nunn, J. L., Bruun, J. A., & Johansen, T. (2009). A role for NBR1 in autophagosomal degradation of ubiquitinated substrates. *Molecular Cell*, 33(4), 505–516. <https://doi.org/10.1016/j.molcel.2009.01.020>
25. Itakura, E., & Mizushima, N. (2011). p62 Targeting to the autophagosome formation site requires self-oligomerization but not LC3 binding. *Journal of Cell Biology*, 192(1), 17–27. <https://doi.org/10.1083/jcb.201009067>
26. Pavel, M., Park, S. J., Frake, R. A., Son, S. M., Manni, M. M., Bento, C. F., Renna, M., Ricketts, T., Menzies, F. M., Tanasa, R., & Rubinshtein, D. C. (2021). alpha-Catenin levels determine direction of YAP/TAZ response to autophagy perturbation. *Nature Communication*, 12(1), 1703. <https://doi.org/10.1038/s41467-021-21882-1>
27. Schlegelmilch, K., Mohseni, M., Kirak, O., Pruszk, J., Rodriguez, J. R., Zhou, D., Kreger, B. T., Vasioukhin, V., Avruch, J., Brummelkamp, T. R., & Camargo, F. D. (2011). Yap1 acts downstream of alpha-catenin to control epidermal proliferation. *Cell*, 144(5), 782–795. <https://doi.org/10.1016/j.cell.2011.02.031>
28. Vite, A., Zhang, C., Yi, R., Emms, S., & Radice, G. L. (2018). alpha-Catenin-dependent cytoskeletal tension controls Yap activity in the heart. *Development (Cambridge, England)*, 145(5), <https://doi.org/10.1242/dev.149823>
29. Sarpal, R., Yan, V., Kazakova, L., Sheppard, L., Yu, J. C., Fernandez-Gonzalez, R., & Tepass, U. (2019). Role of alpha-Catenin and its mechanosensing properties in regulating Hippo/YAP-dependent tissue growth. *Plos Genetics*, 15(11), e1008454. <https://doi.org/10.1371/journal.pgen.1008454>
30. Pavel, M., Park, S. J., Tanasa, R., & Rubinshtein, D. C. (2021). Cell type-specific YAP1-WWTR1/TAZ transcriptional responses after autophagy perturbations are determined by levels of alpha-catenins (CTNNA1 and CTNNA3). *Autophagy*, 17(7), 1788–1790. <https://doi.org/10.1080/15548627.2021.1934273>
31. Lee, Y. A., Noon, L. A., Akat, K. M., Ybanez, M. D., Lee, T. F., Berres, M. L., & Friedman, S. L. (2018). Autophagy is a gatekeeper of hepatic differentiation and carcinogenesis by controlling the degradation of Yap. *Nature Communication*, 9(1), 4962. <https://doi.org/10.1038/s41467-018-07338-z>
32. Totaro, A., Zhuang, Q., Panciera, T., Battilana, G., Azzolin, L., Brumana, G., Gandin, A., Brusatin, G., Cordenonsi, M., & Piccolo, S. (2019). Cell phenotypic plasticity requires autophagic flux driven by YAP/TAZ mechanotransduction. *Proceedings of the National Academy of Sciences of the United States of America*, 116(36), 17848–17857. <https://doi.org/10.1073/pnas.1908228116>

33. Sun, X., & Tang, D. (2014). HMGB1-dependent and -independent autophagy. *Autophagy*, 10(10), 1873–1876. <https://doi.org/10.4161/auto.32184>
34. Tang, D., Kang, R., Livesey, K. M., Cheh, C. W., Farkas, A., Loughran, P., Hoppe, G., Bianchi, M. E., Tracey, K. J., Zeh, H. J., 3rd, & Lotze, M. T. (2010). Endogenous HMGB1 regulates autophagy. *Journal of Cell Biology*, 190(5), 881–892. <https://doi.org/10.1083/jcb.200911078>
35. Zhao, M., Zhang, Y., Jiang, Y., Wang, K., Wang, X., Zhou, D., Wang, Y., Yu, R., & Zhou, X. (2021). YAP promotes autophagy and progression of gliomas via upregulating HMGB1. *Journal of Experimental & Clinical Cancer Research*, 40(1), 99. <https://doi.org/10.1186/s13046-021-01897-8>
36. Ikeda, S., Nah, J., Shirakabe, A., Zhai, P., Oka, S. I., Sciarretta, S., Guan, K. L., Shimokawa, H., & Sadoshima, J. (2021). YAP plays a crucial role in the development of cardiomyopathy in lysosomal storage diseases. *Journal of Clinical Investigation*, 131(5), <https://doi.org/10.1172/JCI143173>
37. Song, Q., Mao, B., Cheng, J., Gao, Y., Jiang, K., & Chen, J., Yuan, Z., & Meng, S. (2015). YAP enhances autophagic flux to promote breast cancer cell survival in response to nutrient deprivation. *PLoS ONE*, 10(3), e0120790. <https://doi.org/10.1371/journal.pone.0120790>
38. Xu, Y., Xia, X., & Pan, H. (2013). Active autophagy in the tumor microenvironment: A novel mechanism for cancer metastasis. *Oncology Letters*, 5(2), 411–416. <https://doi.org/10.3892/ol.2012.1015>
39. Han, K., Kim, J., & Choi, M. (2014). Quantitative indices of autophagy activity from minimal models. *Theoretical Biology and Medical Modelling*, 11, 31. <https://doi.org/10.1186/1742-4682-11-31>
40. Liang, N., Zhang, C., Dill, P., Panasyuk, G., Pion, D., Koka, V., Gallazzini, M., Olson, E. N., Lam, H., Henske, E. P., Dong, Z., Apte, U., Pallet, N., Johnson, R. L., Terzi, F., Kwiatkowski, D. J., Scazecz, J. Y., Martignoni, G., & Pende, M. (2014). Regulation of YAP by mTOR and autophagy reveals a therapeutic target of tuberous sclerosis complex. *Journal of Experimental Medicine*, 211(11), 2249–2263. <https://doi.org/10.1084/jem.20140341>
41. Rabanal-Ruiz, Y., & Korolchuk, V. I. (2018). mTORC1 and nutrient homeostasis: The central role of the lysosome. *International Journal of Molecular Sciences*, 19(3), 818. <https://doi.org/10.3390/ijms19030818>
42. Mortenson, J. B., Heppler, L. N., Banks, C. J., Weerasekera, V. K., Whited, M. D., Piccolo, S. R., Johnson, W. E., Thompson, J. W., & Andersen, J. L. (2015). Histone deacetylase 6 (HDAC6) promotes the pro-survival activity of 14-3-3zeta via deacetylation of lysines within the 14-3-3zeta binding pocket. *Journal of Biological Chemistry*, 290(20), 12487–12496. <https://doi.org/10.1074/jbc.M114.607580>
43. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009). Lysine acetylation targets protein complexes and co-regulates major cellular functions. *Science*, 325(5942), 834–840. <https://doi.org/10.1126/science.1175371>
44. Zhang, X., Qiao, Y., Wu, Q., Chen, Y., Zou, S., Liu, X., Zhu, G., Zhao, Y., Chen, Y., Yu, Y., Pan, Q., Wang, J., & Sun, F. (2017). The essential role of YAP O-GlcNAcylation in high-glucose-stimulated liver tumorigenesis. *Nature Communication*, 8, 15280. <https://doi.org/10.1038/ncomms15280>
45. Jin, M., & Klionsky, D. J. (2014). Regulation of autophagy: Modulation of the size and number of autophagosomes. *Febs Letters*, 588(15), 2457–2463. <https://doi.org/10.1016/j.febslet.2014.06.015>
46. Backues, S. K., Chen, D., Ruan, J., & Xie, Z., & Klionsky, D. J. (2014). Estimating the size and number of autophagic bodies by electron microscopy. *Autophagy*, 10(1), 155–164. <https://doi.org/10.4161/auto.26856>
47. Delorme-Axford, E., Guimaraes, R. S., & Reggiori, F., & Klionsky, D. J. (2015). The yeast *Saccharomyces cerevisiae*: An overview of methods to study autophagy progression. *Methods (San Diego, Calif.)*, 75, 3–12. <https://doi.org/10.1016/j.ymeth.2014.12.008>
48. Loos, B., du Toit, A., & Hofmeyr, J. H. (2014). Defining and measuring autophagosome flux-concept and reality. *Autophagy*, 10(11), 2087–2096. <https://doi.org/10.4161/15548627.2014.973338>
49. Fan, Q., Yang, L., Zhang, X., Ma, Y., Li, Y., & Dong, L., Zong, Z., Hua, X., Su, D., Li, H., & Liu, J. (2018). Autophagy promotes metastasis and glycolysis by upregulating MCT1 expression and Wnt/beta-catenin signaling pathway activation in hepatocellular carcinoma cells. *Journal of Experimental & Clinical Cancer Research*, 37(1), 9. <https://doi.org/10.1186/s13046-018-0673-y>
50. Petherick, K. J., Williams, A. C., Lane, J. D., Ordonez-Moran, P., Huelsken, J., Collard, T. J., Smartt, H. J., Batson, J., Malik, K., Paraskeva, C., & Greenhough, A. (2013). Autolysosomal beta-catenin degradation regulates Wnt-autophagy-p62 crosstalk. *Embo Journal*, 32(13), 1903–1916. <https://doi.org/10.1038/emboj.2013.123>
51. Gao, C., Cao, W., Bao, L., Zuo, W., Xie, G., Cai, T., Fu, W., Zhang, J., Wu, W., Zhang, X., & Chen, Y. G. (2010). Autophagy negatively regulates Wnt signalling by promoting Dishevelled degradation. *Nature Cell Biology*, 12(8), 781–790. <https://doi.org/10.1038/ncb2082>
52. Jing, Q., Li, G., Chen, X., Liu, C., Lu, S., Zheng, H., Ma, H., Qin, Y., Zhang, D., Zhang, S., Ren, S., Huang, D., Tan, P., Chen, J., Qiu, Y., & Liu, Y. (2019). Wnt3a promotes radioresistance via autophagy in squamous cell carcinoma of the head and neck. *Journal of Cellular and Molecular Medicine*, 23(7), 4711–4722. <https://doi.org/10.1111/jcmm.14394>
53. Su, N., & Wang, P., & Li, Y. (2016). Role of Wnt/beta-catenin pathway in inducing autophagy and apoptosis in multiple myeloma cells. *Oncology Letters*, 12(6), 4623–4629. <https://doi.org/10.3892/ol.2016.5289>
54. Nager, M., Sallan, M. C., Visa, A., Pushparaj, C., Santacana, M., Macia, A., Yeramian, A., Cantí, C., & Herreros, J. (2018). Inhibition of WNT-CTNNB1 signaling upregulates SQSTM1 and sensitizes glioblastoma cells to autophagy blockers. *Autophagy*, 14(4), 619–636. <https://doi.org/10.1080/15548627.2017.1423439>
55. Cicchini, M., Chakrabarti, R., Kongara, S., Price, S., Nahar, R., Lozy, F., Zhong, H., Vazquez, A., Kang, Y., & Karantza, V. (2014). Autophagy regulator BECN1 suppresses mammary tumorigenesis driven by WNT1 activation and following parity. *Autophagy*, 10(11), 2036–2052. <https://doi.org/10.4161/auto.34398>
56. Alizadeh, J., Glogowska, A., Thliveris, J., Kalantari, F., Shojaei, S., Hombach-Klonisch, S., Klonisch, T., & Ghavami, S. (2018). Autophagy modulates transforming growth factor beta 1 induced epithelial to mesenchymal transition in non-small cell lung cancer cells. *Biochim Biophys Acta Molecular Cell Research*, 1865(5), 749–768. <https://doi.org/10.1016/j.bbamcr.2018.02.007>
57. Sun, Y., Xiong, L., Wang, X., Wang, L., Chen, B., Huang, J., Huang, M., Chen, J., Wu, J., Huang, S., & Liu, Y. (2021). Autophagy inhibition attenuates TGF-beta2-induced epithelial-mesenchymal transition in lens epithelial cells. *Life Sciences*, 265, 118741. <https://doi.org/10.1016/j.lfs.2020.118741>
58. Nettesheim, A., Shim, M. S., Hirt, J., & Liton, P. B. (2019). Transcriptome analysis reveals autophagy as regulator of TGFbeta/Smad-induced fibrogenesis in trabecular meshwork cells. *Science Reports*, 9(1), 16092. <https://doi.org/10.1038/s41598-019-52627-2>
59. Pokharel, S. M., Shil, N. K., & Bose, S. (2016). Autophagy, TGF-beta, and SMAD-2/3 signaling regulates interferon-beta response in respiratory syncytial virus infected macrophages. *Frontiers in Cellular and Infection Microbiology*, 6, 174. <https://doi.org/10.3389/fcimb.2016.00174>
60. Ding, Y., Kim, S., Lee, S. Y., Koo, J. K., Wang, Z., & Choi, M. E. (2014). Autophagy regulates TGF-beta expression and suppresses kidney fibrosis induced by unilateral ureteral obstruction. *Journal of the American Society of Nephrology*, 25(12), 2835–2846. <https://doi.org/10.1681/ASN.2013101068>
61. Ghavami, S., Cunnington, R. H., Gupta, S., Yeganeh, B., Filomeno, K. L., Freed, D. H., Chen, S., Klonisch, T., Halayko, A. J., Ambrose, E., Singal, R., & Dixon, I. M. (2015). Autophagy is a regulator of TGF-beta1-induced fibrogenesis in primary human atrial

- myofibroblasts. *Cell Death & Disease*, 6, e1696. <https://doi.org/10.1038/cddis.2015.36>
62. Kiyono, K., Suzuki, H. I., Matsuyama, H., Morishita, Y., Komuro, A., Kano, M. R., Sugimoto, K., & Miyazono, K. (2009). Autophagy is activated by TGF-beta and potentiates TGF-beta-mediated growth inhibition in human hepatocellular carcinoma cells. *Cancer Research*, 69(23), 8844–8852. <https://doi.org/10.1158/0008-5472.CAN-08-4401>
 63. Gajewska, M., Gajkowska, B., & Motyl, T. (2005). Apoptosis and autophagy induced by TGF-B1 in bovine mammary epithelial BME-UV1 cells. *Journal of Physiology and Pharmacology*, 56(3), 143–157.
 64. He, R., Wang, M., Zhao, C., Shen, M., Yu, Y., He, L., Zhao, Y., Chen, H., Shi, X., Zhou, M., Pan, S., Liu, Y., Guo, X., Li, X.u., & Qin, R. (2019). TFEB-driven autophagy potentiates TGF-beta induced migration in pancreatic cancer cells. *Journal of Experimental & Clinical Cancer Research*, 38(1), 340. <https://doi.org/10.1186/s13046-019-1343-4>
 65. Colleran, A., Ryan, A., O'Gorman, A., Mureau, C., Liptrot, C., Dockery, P., Fearnhead, H., & Egan, L. J. (2011). Autophagosomal I kappa B alpha degradation plays a role in the long term control of tumor necrosis factor-alpha-induced nuclear factor-kappaB (NF-kappaB) activity. *Journal of Biological Chemistry*, 286(26), 22886–22893. <https://doi.org/10.1074/jbc.M110.199950>
 66. Qing, G., Yan, P., & Xiao, G. (2006). Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of I kappa B kinase (IKK). *Cell Research*, 16(11), 895–901. <https://doi.org/10.1038/sj.cr.7310109>
 67. Kim, J. E., You, D. J., Lee, C., Ahn, C., Seong, J. Y., & Hwang, J. I. (2010). Suppression of NF-kappaB signaling by KEAP1 regulation of IKKbeta activity through autophagic degradation and inhibition of phosphorylation. *Cell Signal*, 22(11), 1645–1654. <https://doi.org/10.1016/j.cellsig.2010.06.004>
 68. Niida, M., Tanaka, M., & Kamitani, T. (2010). Downregulation of active IKK beta by Ro52-mediated autophagy. *Molecular Immunology*, 47(14), 2378–2387. <https://doi.org/10.1016/j.molimm.2010.05.004>
 69. Liu, K., Zhang, L., Zhao, Q., Zhao, Z., Zhi, F., Qin, Y., & Cui, J. (2018). SKP2 attenuates NF-kappaB signaling by mediating IKKbeta degradation through autophagy. *Journal of Molecular Cell Biology*, 10(3), 205–215. <https://doi.org/10.1093/jmcb/mjy012>
 70. Ye, Y., Tan, S., Zhou, X., Li, X., Jundt, M. C., Lichter, N., Dhasarathy, A., & Wu, M. (2015). Inhibition of p-IkappaBalpha ubiquitylation by autophagy-related gene 7 to regulate inflammatory responses to bacterial infection. *Journal of Infectious Diseases*, 212(11), 1816–1826. <https://doi.org/10.1093/infdis/jiv301>
 71. Peng, X., Wang, Y., Li, H., Fan, J., Shen, J., Yu, X., Zhou, Y.i, & Mao, H. (2019). ATG5-mediated autophagy suppresses NF-kappaB signaling to limit epithelial inflammatory response to kidney injury. *Cell Death & Disease*, 10(4), 253. <https://doi.org/10.1038/s41419-019-1483-7>
 72. Comb, W. C., Cogswell, P., Sitcheran, R., & Baldwin, A. S. (2011). IKK-dependent, NF-kappaB-independent control of autophagic gene expression. *Oncogene*, 30(14), 1727–1732. <https://doi.org/10.1038/onc.2010.553>
 73. Lin, F., Ghislat, G., Luo, S., Renna, M., Siddiqi, F., & Rubinsztein, D. C. (2015). XIAP and cIAP1 amplifications induce Beclin 1-dependent autophagy through NFkappaB activation. *Human Molecular Genetics*, 24(10), 2899–2913. <https://doi.org/10.1093/hmg/ddv052>
 74. Sarkar, S., Korolchuk, V. I., Renna, M., Imarisio, S., Fleming, A., Williams, A., Garcia-Arencibia, M., Rose, C., Luo, S., Underwood, B. R., Kroemer, G., O'Kane, C. J., & Rubinsztein, D. C. (2011). Complex inhibitory effects of nitric oxide on autophagy. *Molecular Cell*, 43(1), 19–32. <https://doi.org/10.1016/j.molcel.2011.04.029>
 75. Djavaheri-Mergny, M., Amelotti, M., Mathieu, J., Besancon, F., Bauvy, C., Souquere, S., Pierron, G., & Codogno, P. (2006). NF-kappaB activation represses tumor necrosis factor-alpha-induced autophagy. *Journal of Biological Chemistry*, 281(41), 30373–30382. <https://doi.org/10.1074/jbc.M602097200>
 76. Verzella, D., Pescatore, A., Capece, D., Vecchiotti, D., Ursini, M. V., Franzoso, G., Alesse, E., & Zazzeroni, F. (2020). Life, death, and autophagy in cancer: NF-kappaB turns up everywhere. *Cell Death & Disease*, 11(3), 210. <https://doi.org/10.1038/s41419-020-2399-y>
 77. Catz, S. D., & Johnson, J. L. (2001). Transcriptional regulation of bcl-2 by nuclear factor kappa B and its significance in prostate cancer. *Oncogene*, 20(50), 7342–7351. <https://doi.org/10.1038/sj.onc.1204926>
 78. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S., Jr. (1998). NF-kappaB antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. *Science*, 281(5383), 1680–1683. <https://doi.org/10.1126/science.281.5383.1680>
 79. Bavi, P., Uddin, S., Bu, R., Ahmed, M., Abubaker, J., Balde, V., Qadri, Z., Ajarim, D., Al-Dayel, F., Hussain, A. R., & Al-Kuraya, K. S. (2011). The biological and clinical impact of inhibition of NF-kappaB-initiated apoptosis in diffuse large B cell lymphoma (DLBCL). *Journal of Pathology*, 224(3), 355–366. <https://doi.org/10.1002/path.2864>
 80. Karin, M., & Lin, A. (2002). NF-kappaB at the crossroads of life and death. *Nature Immunology*, 3(3), 221–227. <https://doi.org/10.1038/ni0302-221>
 81. Luo, J. L., Kamata, H., & Karin, M. (2005). IKK/NF-kappaB signaling: Balancing life and death – A new approach to cancer therapy. *Journal of Clinical Investigation*, 115(10), 2625–2632. <https://doi.org/10.1172/JCI26322>
 82. Baldwin, A. S. (2012). Regulation of cell death and autophagy by IKK and NF-kappaB: Critical mechanisms in immune function and cancer. *Immunological Reviews*, 246(1), 327–345. <https://doi.org/10.1111/j.1600-065X.2012.01095.x>
 83. Kapuy, O., Vinod, P. K., Mandl, J., & Banhegyi, G. (2013). A cellular stress-directed bistable switch controls the crosstalk between autophagy and apoptosis. *Molecular Biosystems*, 9(2), 296–306. <https://doi.org/10.1039/c2mb25261a>
 84. Tsuboi, Y., Kurimoto, M., Nagai, S., Hayakawa, Y., Kamiyama, H., Hayashi, N., Kitajima, I., & Endo, S. (2009). Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kappa B activation in human glioma cell lines. *Journal of Neurosurgery*, 110(3), 594–604. <https://doi.org/10.3171/2008.8.JNS17648>
 85. Dutta, J., Fan, Y., Gupta, N., Fan, G., & Gelinas, C. (2006). Current insights into the regulation of programmed cell death by NF-kappaB. *Oncogene*, 25(51), 6800–6816. <https://doi.org/10.1038/sj.onc.1209938>
 86. Karin, M. (2006). Nuclear factor-kappaB in cancer development and progression. *Nature*, 441(7092), 431–436. <https://doi.org/10.1038/nature04870>
 87. Chen, S. M., Li, Y. Y., Tu, C. H., Salazar, N., Tseng, Y. Y., Huang, S. F., Hsieh, L.-L., & Lui, T. N. (2016). Blockade of inhibitors of apoptosis proteins in combination with conventional chemotherapy leads to synergistic antitumor activity in medulloblastoma and cancer stem-like cells. *Plos One*, 11(8), e0161299. <https://doi.org/10.1371/journal.pone.0161299>
 88. Wang, N., Feng, Y., Zhu, M., Siu, F. M., Ng, K. M., & Che, C. M. (2013). A novel mechanism of XIAP degradation induced by timosaponin AIII in hepatocellular carcinoma. *Biochimica Et Biophysica Acta*, 1833(12), 2890–2899. <https://doi.org/10.1016/j.bbamcr.2013.07.018>
 89. Singh, B. N., Kumar, D., Shankar, S., & Srivastava, R. K. (2012). Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells. *Biochemical Pharmacology*, 84(9), 1154–1163. <https://doi.org/10.1016/j.bcp.2012.08.007>

90. Gradzka, S., Thomas, O. S., Kretz, O., Haimovici, A., Vasilikos, L., Wong, W. W., Häcker, G., & Gentle, I. E. (2018). Inhibitor of apoptosis proteins are required for effective fusion of autophagosomes with lysosomes. *Cell Death & Disease*, 9(5), 529. <https://doi.org/10.1038/s41419-018-0508-y>
91. Huang, X., Wu, Z., Mei, Y., & Wu, M. (2013). XIAP inhibits autophagy via XIAP-Mdm2-p53 signalling. *Embo Journal*, 32(16), 2204–2216. <https://doi.org/10.1038/emboj.2013.133>
92. Huang, X., Wang, X. N., Yuan, X. D., Wu, W. Y., Lobie, P. E., & Wu, Z. (2019). XIAP facilitates breast and colon carcinoma growth via promotion of p62 depletion through ubiquitination-dependent proteasomal degradation. *Oncogene*, 38(9), 1448–1460. <https://doi.org/10.1038/s41388-018-0513-8>
93. Son, S. M., Park, S. J., Fernandez-Estevez, M., & Rubinsztein, D. C. (2021). Autophagy regulation by acetylation-implications for neurodegenerative diseases. *Experimental & Molecular Medicine*, 53(1), 30–41. <https://doi.org/10.1038/s12276-021-00556-4>
94. Son, S. M., Park, S. J., Stamatakou, E., Vicinanza, M., & Menzies, F. M., & Rubinsztein, D. C. (2020). Leucine regulates autophagy via acetylation of the mTORC1 component raptor. *Nature Communication*, 11(1), 3148. <https://doi.org/10.1038/s41467-020-16886-2>
95. Son, S. M., Park, S. J., Lee, H., Siddiqi, F., Lee, J. E., & Menzies, F. M., & Rubinsztein, D. C. (2019). Leucine signals to mTORC1 via its metabolite Acetyl-Coenzyme A. *Cell Metabolism*, 29(1), 192–201.e7. <https://doi.org/10.1016/j.cmet.2018.08.013>
96. Loos, B., Klionsky, D. J., Du Toit, A., & Hofmeyr, J. S. (2020). On the relevance of precision autophagy flux control in vivo – Points of departure for clinical translation. *Autophagy*, 16(4), 750–762. <https://doi.org/10.1080/15548627.2019.1687211>
97. Toit, A. D., Loos, B., & Hofmeyr, J. H. S. (2020). Supply and demand analysis of autophagy. *Methods in Molecular Biology*, 2088, 345–357. https://doi.org/10.1007/978-1-0716-0159-4_16
98. Denton, D., & Kumar, S. (2019). Autophagy-dependent cell death. *Cell Death and Differentiation*, 26(4), 605–616. <https://doi.org/10.1038/s41418-018-0252-y>
99. Kriel, J., & Loos, B. (2019). The good, the bad and the autophagosome: Exploring unanswered questions of autophagy-dependent cell death. *Cell Death and Differentiation*, 26(4), 640–652. <https://doi.org/10.1038/s41418-018-0267-4>
100. Tavassoly, I., Parmar, J., Shajahan-Haq, A. N., Clarke, R., Baumann, W. T., & Tyson, J. J. (2015). Dynamic modeling of the interaction between autophagy and apoptosis in mammalian cells. *CPT: Pharmacometrics & Systems Pharmacology*, 4(4), 263–272. <https://doi.org/10.1002/psp4.29>
101. Kapuy, O., Holczer, M., Marton, M., & Korcsmaros, T. (2021). Autophagy-dependent survival is controlled with a unique regulatory network upon various cellular stress events. *Cell Death & Disease*, 12(4), 309. <https://doi.org/10.1038/s41419-021-03599-7>

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher's website.

How to cite this article: Pavel, M., Tanasa, R., Park, So J, & Rubinsztein, D. C. (2022). The complexity of biological control systems: an autophagy case study. *BioEssays*, 44, e2100224. <https://doi.org/10.1002/bies.202100224>